Information  X 
Enter a valid email address

Xenova Group plc (XEN)

  Print      Mail a friend

Monday 21 June, 2004

Xenova Group plc

Xenova Group plc

Xenova Receives Manufacturer's Authorisation from MHRA

Slough, UK, 21 June 2004 - Xenova Group plc (London Stock Exchange:
XEN; NASDAQ: XNVA) announced today that it has received a
Manufacturer's Authorisation - Investigational Medicinal Products
from the Medicines and Healthcare products Regulatory Agency (MHRA)
for its clinical trials manufacturing facility (CTMF) in Cambridge.

This authorisation allows Xenova to manufacture and release
investigational medicinal products (IMPs) in compliance with the new
Clinical Trials Directive which came into force in May of this year.
The authorisation will apply to Xenova's own products and those
manufactured at Xenova under contract for clients.  The licence was
awarded after the MHRA inspected the company's premises and confirmed
compliance with the EU Good Manufacturing Practices (GMP), which
Xenova received in September 2003.

Mike Johnston, Director of Manufacturing and Process Development at
Xenova, said "This authorisation confirms that we are compliant with
manufacturing standards that are required under the new clinical
trials directive and through the utilisation of excess capacity we
can assist other companies in the production of GMP products as well
as ensure all Xenova products manufactured at the CTMF are of the
highest clinical standard."

Xenova Group plc is a UK-based biopharmaceutical company focused on
the development of novel drugs to treat cancer and addiction with a
secondary focus in immunotherapy.  The Company has a broad pipeline
of products in clinical development, including three cancer
programmes:  its lead product TransMIDTM, for the treatment of
high-grade glioma, is in Phase III trials, and its novel DNA
targeting agents and XR303 are both in Phase I for cancer
indications.  Xenova is also developing two therapeutic vaccines for
cocaine and nicotine addiction, which are in Phase II and Phase I
trials respectively.  Quoted on the London Stock Exchange (XEN) and
on NASDAQ (XNVA), Xenova employs approximately 112 people throughout
its sites in the UK and North America. (Reuters XEN.L; Bloomberg XEN
For further information about Xenova and its products please visit
the Xenova website at

Disclaimer to take advantage of the "Safe Harbor" provisions of the
US Private Securities Litigation Reform Act of 1995. This press
release contains "forward-looking statements," including statements
about our ability to commercialize products. Various risks may cause
Xenova's actual results to differ materially from those expressed or
implied by the forward looking statements, including: unexpected
costs; commercial limitations imposed by patents owned or controlled
by third parties; our dependence upon strategic alliance partners to
develop and commercialize products and services; difficulties or
delays in obtaining regulatory approvals to market products and
services resulting from our development efforts; the requirement for
substantial funding to conduct research and development and to expand
commercialization activities; and product initiatives by
competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the
Securities and Exchange Commission.  We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.


Xenova Group plc
+44 (0)1753 706600
David A. Oxlade, Chief Executive Officer
Daniel Abrams, Finance Director
Veronica Cefis Sellar, Head of Corporate Communications

UK - Financial Dynamics
+44 (0)20 7831 3113
David Yates
Ben Atwell

US - Trout Group/BMC Communications
+1 212 477 9007
Media: Brad Miles
Investors: Lee Stern